首页> 外文OA文献 >Results of cross-sectional epidemiologic study on determination of recombinant biological agents requirement for treatment of patients with rheumatoid arthritis in real-life clinical practice. Report 1. Demographic, social, clinicaland laboratory characteristics of Russian patients with rheumatoid arthritis

【2h】

Results of cross-sectional epidemiologic study on determination of recombinant biological agents requirement for treatment of patients with rheumatoid arthritis in real-life clinical practice. Report 1. Demographic, social, clinicaland laboratory characteristics of Russian patients with rheumatoid arthritis

机译：真生临床实践中类风湿性关节炎患者治疗重组生物学试剂的横截面流行病学研究的结果。报告1.俄罗斯类风湿性关节炎患者的人口，社会，临床实验室特征

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
S F Erdes; O M Folomeeva; E A Galishko; M Y Telnyh;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents? [J] . Mark C. Genovese, Arthur Kavanaugh, Michael E. Weinblatt, Arthritis & Rheumatism . 2011,第2期

机译：口服Syk激酶抑制剂治疗类风湿关节炎：为期3个月的随机，安慰剂对照II期研究，用于对生物制剂无反应的活动性类风湿关节炎患者？
2. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. [J] . Genovese MC, Kavanaugh A, Weinblatt ME, Arthritis and Rheumatism . 2011,第2期

机译：口服Syk激酶抑制剂治疗类风湿性关节炎：为期3个月的随机，安慰剂对照，II期研究，用于对生物制剂无反应的活动性类风湿性关节炎患者。
3. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON) [J] . Smolen Josef S., Kremer Joel M., Gaich Carol L., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第4期

机译：来自类风湿性关节炎患者的患者患者的患者报告的结果III研究和对生物药物的反应不足（RA-BEACON）
4. Immunogenic HLA-DR-presented-peptides Identified from Clinical Samples of Synovial Tissue/Fluid and Peripheral Blood from Patients with Rheumatoid Arthritis or Lyme Arthritis [C] . Qi Wang, Elise E. Drouin, Chunxiang Yao, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：免疫原性HLA-DR呈递肽，从类风湿性关节炎或莱姆关节炎患者的滑膜组织/液体和外周血的临床样本中鉴定出来
5. Clinical studies of immunomodulatory activities of Yunzhi -Danshen in breast cancer and nasopharyngeal carcinoma patients, and Lingzhi-San Miao San in rheumatoid arthritis patients. [D] . Bao, Yixi. 2005

机译：云芝丹参对乳腺癌和鼻咽癌患者及类风湿关节炎灵芝三妙散的免疫调节活性的临床研究。
6. Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting [O] . Mayara Costa de Camargo, Bruna Cipriano Almeida Barros, Izabela Fulone, -1

机译：在现实生活中接受长期生物制剂治疗的类风湿关节炎和银屑病关节炎患者的不良事件
7. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE) [O] . Josef S. Smolen, Jürgen Wollenhaupt, Juan J. Gomez-Reino, 2015

机译：根据新的ACR-EULAR标准在早期接受类风湿关节炎的阿巴西普治疗患者中的临床缓解的实现情况和特征：从Abatacept研究到未接受甲氨蝶呤（MTX）的早期侵蚀性类风湿关节炎患者的量表缓解和关节损伤进展的新分析（同意）

著录项

引文网络

相似文献

相关主题

期刊订阅